Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests could reveal who benefits from Next-Gen lymphoma antibodies

NCT ID NCT07767799

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This observational study is looking at whether biological markers in blood, tumor tissue, and imaging scans can predict how well patients with B-cell non-Hodgkin lymphoma respond to treatment with novel monoclonal antibodies. Researchers will collect samples from about 1,000 adults receiving these therapies as part of routine care, and analyze genetic, immune, and metabolic features. The goal is to find patterns that could help doctors personalize treatment and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Novel monoclonal antibodies (including bispecific antibodies, immunoconjugates, and naked antibodies) used as standard-of-care treatment
What this could lead to
If successful, this could help doctors predict which lymphoma patients will respond best to antibody therapies, potentially guiding more personalized treatment decisions.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients or treatments, and the biomarkers studied may not reliably predict outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2041

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Being an observational translational study primarily aimed at descriptive and exploratory analyses, no formal statistical hypothesis testing is planned for BIO-FIL\_MAB. The sample size is therefore determined based on feasibility and the expected availability of patients participating in the parent FIL-MAB clinical cohort. Overall, it is anticipated that at least 1000 patients will be enrolled and followed, providing a robust population for integrated biology, immunology, and imaging analyses alongside clinical outcomes.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years old) are diagnosed with B-cell Non-Hodgkin Lymphoma; * Patients enrolled in the FIL\_MAB trial (provided by Informed Consent Form (ICF) signature) who are scheduled to receive treatment with novel monoclonal antibodies (NMABs), either as monotherapy or in combination with other therapies; * Written informed consent to participate in this study. Exclusion Criteria: * Patients not enrolled in the FIL\_MAB study. * Evidence of other clinically significant uncontrolled condition(s) including, but not limited to: * Uncontrolled and/or active systemic infection (viral, bacterial or fungal), including active ongoing infection from SARSCoV-2; * Chronic or acute hepatitis B (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e., HBsAg negative, HBsAb positive and HBcAb negative) or positive HBcAb from previous infection or intravenous immunoglobulins (IVIG) may participate; inactive carriers (HBsAg positive with undetectable HBV- DNA) are eligible. Patients with presence of HCV antibody are eligible only if PCR negative for HCV-RNA; * HIV seropositivity; * Refusal or inability to provide informed consent. * Refusal or inability to provide biological specimens.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-cell non-Hodgkin lymphoma (NHL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-cell non-Hodgkin lymphoma (NHL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dipartimento di Medicina Traslazionale e di Precisione - Istituto Ematologia - Policlinico Umberto I - Università "La Sapienza" - Roma

    Roma, 00161, Italy

  • Divisione di Oncologia e dei Tumori immuno-correlati - IRCCS Centro di Riferimento Oncologico di Aviano

    Aviano, 33081, Italy

  • Ematologia - ASST Spedali Civili di Brescia

    Brescia, 25123, Italy

  • Ematologia - Arcispedale Santa Maria Nuova - IRCCS -Azienda Unità Sanitaria Locale

    Reggio Emilia, 42123, Italy

  • Ematologia - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

    Milan, 20133, Italy

  • Ematologia - Fondazione del Piemonte per l'Oncologia - IRCCS

    Candiolo, Torino, 10060, Italy

  • Ematologia - Ospedale S. Bortolo - ULSS 8 Berica

    Vicenza, 36100, Italy

  • Ematologia Universitaria - A.O.U. Città della Salute e della Scienza di Torino

    Torino, 10126, Italy

  • Istituto di Ematologia "Seragnoli" - Policlinico S.Orsola-Malpighi

    Bologna, 40138, Italy

  • Oncoematologia IOV - Ospedale di Castelfranco Veneto

    Castelfranco Veneto, Treviso, 31033, Italy

  • S.C. Ematologia - A.O. S. Croce e Carle

    Cuneo, 12100, Italy

  • S.C. Ematologia - A.O.U. Città della Salute e della Scienza di Torino

    Torino, 10126, Italy

  • SC Ematologia - ASST Grande Ospedale Metropolitano Niguarda

    Milan, 20162, Italy

  • SC Ematologia - Azienda Ospedaliera Papa Giovanni XXIII - Bergamo

    Bergamo, 24127, Italy

  • SCDU Ematologia - AOU Maggiore della Carità di Novara

    Novara, 28100, Italy

  • SCDU Ematologia -AOU SS. Antonio e Biagio e Cesare Arrigo di Alessandria

    Alessandria, 15121, Italy

  • U.O. Ematologia - AOU Integrata di Verona

    Verona, 37134, Italy

  • U.O.C Ematologia - IRCCS Istituto Tumori Giovanni Paolo II - Bari

    Bari, 70124, Italy

  • UOC Ematologia Dipartimento Oncologico Ematologico - P.O. Spirito Santo di Pescara - ASL Pescara

    Pescara, 65124, Italy

  • Unità funzionale di Ematologia -Azienda Ospedaliera Universitaria Careggi

    Florence, 50141, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.